AstraZeneca Fast Rides MA Train Wages 100M Cash on T Cell

AstraZeneca Fast Rides M&A Train, Wages $100M Cash on T-Cell Engager

On Tuesday, June 14, Endpoints News EIC John Carroll sat down with a group of biotech executives to discuss the bear market in industrial stocks and how to deal with it. Here’s the conversation, slightly edited for brevity.

Martin Meeson, sponsor opening:

Thank you John Hello, everyone. My name is Martin Meeson, I am the CEO of Fujifilm Diosynth. For those of you not familiar with Fujifilm Diosynth, we are engaged in clinical and commercial product scale-up development, we have facilities in Europe and the US and approximately 4,000 employees. We run about 150 programs on average, so in terms of managing turbulent times over the past two years, we’ve had quite a bit of experience with that. Not only are we keeping the clinical pipelines and the commercial pipelines open, but also our response to the pandemic and the molecules that we had in it. One of the phrases I probably coined about a year ago when we were chatting at JP Morgan was that I was talking about getting through turbulent times. Well, it has become a fact that we don’t manage and lead through these times, we manage within them, which is actually why that is the purpose and theme we have today.

Endpoints Premium

Premium subscription required

Unlock this item along with other benefits by subscribing to one of our paid plans.